Miscellaneous Preparations

8 Drugs classified under this therapeutic system

Lung Surfactant. Phospholipid fraction from porcine lung 80 mg/ml.
VIALS (sterile susp.): 1 x 5 ml cont. 1.5 ml
(120 mg), 3 ml (240 mg). Single dose of
100-200 mg/kg bdy wt. intratracheal.
Further admin. 1 or 2 other doses of
100 mg/kg bdy. wt. at 6-12 hr. intervals
in babies still being ventilated if FIO2
is greater than 0.40.
See lit.
Preterm babies with RDS (Respiratory
Stress Syndrome).

PDE4 Inhibitor. Roflumilast 500 mcg.
F.C. TABS.: 30,90. 1 tab. once dly.
Maint. tmt. of severe COPD (FEV1 postbronchodilat.
less than 50% predicted)
assoc. with chron. bronchitis in adult pts. with a hist. of freq. exacerb. as add on to
bronchodilat. tmt.
C/I: Hypersens., Moder./severe hep.
impair. (Child-Pugh B or C).

Immunosuppressant. Pirfenidone 267 mg.
HARD CAPS.: 252, 270. The recom. dly.
dose is 801 mg(3 caps.) × 3/d with food
for a total of 2403 mg/day. See lit.
Tmt. of mild to moder. idiop. pulmon.
fibrosis in adult.
C/I: Hypersens. Hist.of angioed. with
pirfenidone. Concom. use of fluvoxamine. Sev. hep. impair. or end stage liver dis. Sev. renal impair.(CrCl <30 ml/min) or end stage
renal dis. requir. dialysis.

Immunosuppressant. Pirfenidone 801 mg.

Alpha 1-antitrypsin (AAT) 1 g / 50 ml.
VIAL (sol. for infus.): 1 x 50 ml. I.V. use
only. 60 mg/kg bdy. wt. 1 x wkly.
See lit.
Chron. augmentat./maint. ther. congen.
defic. alpha1-proteinase inhib. (Alpha1-
PI), also known as alpha1-antitrypsin
(AAT) defic. and clin. evidence
emphysema.
C/I: Immunoglobulin A (IgA) defic. with
antibodies against IgA. Hypersens., incl.
anaphylax. to Alpha1-PI product.

Lung Surfactant. Calfactant (as phospholipid) 35 mg/ml.
VIAL (intratracheal susp.): 3, 6 x 6 ml. 3
ml / kg bdy. wt. at birth. Can be
repeated if necess. every 12 hrs, up to
total of 3 doses. Do not dilute, shake
or sonicate. May req. gentle swirl or
agitat. for redisperse.
Prevent respir. distress syndr. (RDS) in
prem. inf. at high risk for RDS, tmt. prem.
inf. who develop RDS.